WALTHAM, MA, USA & SHANGHAI, China – April 9, 2013 - PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced a new collaboration with the National Center for Drug Screening (NCDS) to advance personalized medicine and drug profiling in China.  PerkinElmer and NCDS will share knowledge, expertise and innovative capabilities to establish a personalized drug research and development platform (Translational Medicine Collaboration Center) for the benefit of Chinese hospitals and patients. Special guests including key governmental leaders, Mr. Jianjun Cheng (CCP Secretary of Shanghai Institute of Materia Medica, Chinese Academy of Sciences), Mr. Jian Zhang (Chief of Econmic Promotion Division) and Mr. Lixin Yu (Deputy Chief of Planning and Finance Division) from Shanghai Zhangjiang INNOPARK Administrative Committee, PerkinElmer’s Chairman and Chief Executive Officer, Mr. Robert F. Friel, Dr. Martina Bielefeld-Sévigny (Vice President and General Manager for Asia Pacific of PerkinElmer) and Dr. Ming-Wei Wang, Director of NCDS, among others, participated in a ceremony today celebrating the collaboration at the Chinese National Compound Library in the Zhangjiang Hi-tech Park, Shanghai.

Mr. Friel said, "The ability to develop individualized medical treatment according to individual’s unique genetic makeup is becoming a major trend of today’s medicine and diagnosis. It is an honor for PerkinElmer to collaborate with the National Center for Drug Screening and Chinese scientists to develop a new and innovative technology platform for the well-being of Chinese people.”

The collaboration will include validation of biomarkers for personalized medicine and related informatics solutions. As a part of this program, the two organizations will first undertake a study on metabolic diseases to validate new diagnostics for Asian populations through utilizing next generation sequencing technologies. Once optimized, the technology platform will be able to disseminate its knowledge to hospitals and testing laboratories throughout China. 

"As an important customer and long-term collaborator of PerkinElmer in the field of life sciences and drug discovery, the National Center for Drug Screening is committed to the research and development of new and effective drugs,”   Dr. Ming-Wei Wang said, “For the majority of drugs that are available in China, the respective biomarkers have not yet been fully validated.  We are very excited to build this state-of-the-art personalized medicine program with PerkinElmer that will allow us to offer vital insights to improve the quality of healthcare in China.”

About The National Center for Drug Screening

The National Center for Drug Screening was jointly invested by the Ministry of Science and Technology, the Chinese Academy of Sciences and the Shanghai Municipality Government. At present, it is the only national center specializing in screening for new drugs. As a public technology platform, the Center offers drug screening services and technical consultation to universities, research institutions and pharmaceutical companies nationwide. For further information please visit www.screen.org.cn and www.cncl.org.cn. 

About PerkinElmer

PerkinElmer Inc. is a global leading company dedicating to improve human and environmental health and safety. The company’s reported revenue in 2012 is about $2.1 billion. It has approximately 7,500 employees serving customers from more than 150 countries and regions and is ranked in the S&P 500 Index. For more information, please call 1-877-PKI-NYSE or visit www.perkinelmer.com.

Congratulating notes by Mr. Jianjun Cheng

Ladies and Gentlemen, dear colleagues and friends,

Good afternoon!

Today we take a great pleasure to hold the opening ceremony of the “Translational Medicine Collaboration Center” jointly set up by the National Center for Drug Screening (NCDS), the Chinese National Compound Library (CNCL) and PerkinElmer (USA). On behalf of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, I thank you for attending this important event from your busy schedules.

As a key national R&D installation, CNCL represents China’s current economic strength and research capability. With the strong support from the former Ministry of Health, Chinese Academy of Sciences, Shanghai Municipality, and Pudong local government, CNCL has made a series of important achievements since its establishment, through various collaborations with scientists home and abroad, and with leading high-tech enterprises like PerkinElmer. We are well on our target to become one of the largest compound library in the world.

PerkinElmer is a global leader in provision of health improvement and safety of the environment. It is well recognized globally for its capability of manufacturing advanced life science instruments, informatics and research reagents with a history of over 76 years. In view of our combined international reputation, I believe this collaboration will promote China’s endeavor in drug discovery and enhance the level of international participation. Such collaboration is mutually beneficial and will certainly strengthen the competence of both parties. Finally, I wish every success to the “Translational Medicine Collaboration Center”. Thank you.

Shanghai Daily: Diabetes profiling link-up